PD-L1 as a Biomarker for Immunotherapy Agents in Lung Cancer

Special Reports, NSCLC (Issue 2), Volume 2, Issue 1

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan Kettering Cancer Center, discusses PD-L1 as a potential biomarker for immunotherapy agents for patients with lung cancer.

Read more aboutfrontline treatment considerations for lung cancer > >